TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. (TGTX) is a healthcare company (biotechnology) based in the United States. The share price is $62.75, down 0.02% on the day, which values the company at $9.48B. Price as of 17 Nov 2026, 19:10 UTC, from Yahoo Finance.

Key facts

Share price
$62.75−0.02% today
Market value
$9.48B
P/E ratio
93.7×last 12 months
Forward P/E
24.6×
Funk Score
59/100
Against its own history
Above its usual priceusual price $54.91
200-week average
$28.81118% above
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

TG Therapeutics, Inc. in more detail

TGTX trades at 93.7× its last twelve months' earnings, 24.6× next year's expected earnings, 10.6× sales. Measured against its own history, the price is 14% above what its usual multiples would imply ($54.91) — above its usual price. It sits 118% above its 200-week average of $28.81.

Over the last five fiscal years TG Therapeutics, Inc. has compounded revenue 426.7% a year. Its Funk Score is 59 out of 100 (financial strength 4.7, profitability 5.2, growth 9.3, value 4.2, each out of 10).

In its favour: Operating margin is expanding; High return on invested capital. Worth checking: Beneish M-score flags the accounts; Share count keeps rising.

Compare

Health Care companies of similar size

Side by side:TGTX vs OSCR (TG Therapeutics, Inc. vs Oscar Health)TGTX vs HSIC (TG Therapeutics, Inc. vs Henry Schein)TGTX vs PRAX (TG Therapeutics, Inc. vs Praxis Precision Medicines)TGTX vs MDGL (TG Therapeutics, Inc. vs Madrigal Pharmaceuticals)TGTX vs TWST (TG Therapeutics, Inc. vs Twist Bioscience)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

TG Therapeutics, Inc. (TGTX): questions and answers

What is TGTX's P/E ratio?

TG Therapeutics, Inc. trades at 93.7× its last twelve months' earnings and 24.6× next year's expected earnings. At its fiscal year-ends over the past 3 years the P/E ranged from 10.8× to 200.7×, with a median of 189.8×.

What is TGTX's PEG ratio?

TG Therapeutics, Inc.'s PEG ratio is 1.61 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is TG Therapeutics, Inc.'s market cap?

TG Therapeutics, Inc. is valued at $9.48B at a share price of $62.75.

Is TGTX overvalued or undervalued?

Against its own history, TGTX is above its usual price: the price is 14% above the $54.91 implied by the median multiples it has traded at (price / earnings, price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is TGTX above its 200-week moving average?

Yes. TGTX is 117.8% above its 200-week average of $28.81. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is TG Therapeutics, Inc. growing?

Over the last five fiscal years TG Therapeutics, Inc.'s revenue grew 426.7% a year.

Cite this page

Funkfolio, “TG Therapeutics, Inc. (TGTX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/TGTX

Underlying data: Yahoo Finance; company filings with the SEC.